E76.F Stock Analysis
E7
Uncovered
Neodynamics AB (publ) is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
NeoDynamics AB operates as a medical technology company, which engages in the development of the diagnosis and treatment of breast cancer. The company is headquartered in Lidingoe, Stockholm. The company went IPO on 2018-12-07. The firm focuses on developing and commercializing products for breast cancer screening, imaging, and breast cancer treatments. The Company’s product NeoNavia, enables a pulse biopsy system for ultrasound guided tissue sampling. The company consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumour whilst enabling tissue samples from both breasts and lymph nodes. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at clinics in United Kingdom, Germany, and Sweden.